Table 1 Baseline demographics of the cohort
Total Cohort | TPV/PR | BOC/PR | |
|---|---|---|---|
n = 309 | n = 215 | n = 94 | |
Age – Years, Median (IQR) | 46 (38–54) | 45 (38–54) | 47 (39–56) |
BMI – kg/m2 Median (IQR) | 26.5 (23.5–28.8) | 26.3 (23.9–28.5) | 25.9 (21.4–30.6) |
Male, n (%) | 212/290 (73.1%) | 149/202 (73.8%) | 63/88 (71.6%) |
History of cirrhosis, n (%) | 79/291 (27.1%) | 55/198 (27.8%) | 24/93 (25.8%) |
Treatment Experienced, n (%) | 89/306 (29.1%) | 66/212 (31.1%) | 23/94 (24.5%) |
HIV co-infected, n (%) | 23/313 (7.3%) | 23/198 (11.6%) | – |
IL28B Allele, n (%) | |||
CC | 92/269 (34.2%) | 59/179 (33%) | 31/86 (36%) |
CT | 144/269 (53.5%) | 96/179 (53.6%) | 47/86 (54.5%) |
TT | 33/269 (12.3%) | 24/179 (13.4%) | 8/86 (9.3%) |
Genotype, n (%) | |||
G1a | 172/309 (55.7%) | 119/215 (55.3%) | 53/94 (56.4%) |
G1b | 86/309 (27.8%) | 55/215 (25.6%) | 31/94 (33%) |
G1 – unspecified | 51/309 (16.5%) | 41/215 (19.1%) | 10/94 (10.6%) |
Acquisition Risk Factor | |||
IVDU | 133/309 (43%) | 89/215 (41.7%) | 44/94 (46.8%) |
Anti-D | 28/309 (9.1%) | 18/215 (8.4%) | 10/94 (10.6%) |
Blood product | 36/309 (11.7%) | 31/215 (14.4%) | 5/94 (5.3%) |
Other | 15/309 (4.9%) | 11/215 (5.1%) | 4/94 (4.4%) |
Unknown/not reported | 97/309 (31.4%) | 66/215 (30.7%) | 31/94 (32.9%) |
Baseline HCV-RNA >800,000 IU/ml | 153/286 (53.5%) | 98/196 (50%) | 55/90 (61.1%) |